Would an STK11 mutation influence your choice of single vs combination immunotherapy in a patient with MSI-H metastatic CRC?

The presence of an STK11 mutation would not affect my decision to offer immunotherapy for an MSI-high (dMMR) colorectal cancer patient. There is mixed literature about if this might portend a better response to IO treatment (Kwon et al., PMID 32284250.) One should note that with a KRAS mutation in l...